摘要
目的建立基于高效液相色谱-质谱联用技术(HPLC-MS/MS)测定儿童血浆中厄他培南浓度的方法并考察溶血效应。方法样品经沉淀蛋白法进行前处理,以美罗培南为内标,采用Hypersil GOLD^(TM)柱(2.1 mm×50 mm,3μm)分离;以0.1%甲酸-水和0.1%甲酸-乙腈为流动相,梯度洗脱;质谱检测采用电喷雾离子源正离子扫描方式,多反应监测(MRM)模式;模拟不同程度(0.5%、2%、5%)的溶血样品进行溶血效应考察。结果厄他培南的血药浓度在0.1~50μg·mL^(-1)内呈良好的线性关系(r>0.998 0),方法学验证均符合要求,溶血效应符合标准。结论本方法快速、准确、灵敏、稳定、专属性强,且不受溶血程度为5%以下的溶血效应影响,可应用于厄他培南儿童药动学研究及治疗药物监测。
OBJECTIVE To establish a high performance liquid chromatography-tandem mass spectrometry method for the quantitative analysis of ertapenem in children′s plasma and evaluate the influence caused by hemolytic effect.METHODS Hypersil GOLDTM column(2.1 mm×50 mm,3μm)was used and the column temperature was mainteined at 40℃.The mobile phases was composed of water(A)and acetonitrile(B),each containing 0.1%formic acid.Gradient elution was conducted at a flow rate of 0.5 mL·min-1.The injection volume was 3 mL.Total run time was 4 min.For mass spectrometry,electrospray ionization source was chosen,and positive ion monitoring mode was used with multi-reaction monitoring(MRM)mode.The precursor-to-product ion pairs of ertapenem and meropenem(IS)for quantitation were 476.2→432.2 and 384.1→141.2,respectively.Acetonitrile containing 0.1%formic acid was used as protein precipitation.RESULTS The calibration curve was linear over a range of 0.1 to 50μg·mL-1(r>0.9980,n=6).The within-run and between-run accuracy RSDs were both less than±15%.The within-run and between-run variable coefficients(CV)were both less than 8.5%.No significant matrix effect was observed for ertapenem and the hemolytic effect was acceptable.Ertapenem was stable for 72 h in whole blood at 5℃.Analytes in plasma were stable after three freeze-thaw cycles and robust for 4 h(at room temperature),8 h(in autosampler,5℃)and 30 d(-20℃),respectively.Incurred sample analysis was satisfactory within Ch.P guideline limits.CONCLUSION This rapid,sensitive,robust and exclusive HPLC-MS/MS assay requires small-volume of samples and simple preparation without interference by hemolytic effect,which can be applied in pharmacokinetic studies and therapeutic drug monitoring in children.
作者
张古英
尹志萍
赵德运
王兴华
张中平
高越
ZHANG Gu-ying;YIN Zhi-ping;ZHAO De-yun;WANG Xing-hua;ZHANG Zhong-ping;GAO Yue(Department of Pharmacy,Children's Hospital of Hebei Province,Shijiazhuang 050031,China;Department of Respiration,Children's Hospital of Hebei Province,Shijiazhuang 050031,China;CSPC Ouyi Pharmaceutical Co.,Ltd.,Shijiazhuang 050051,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2020年第22期1867-1872,共6页
Chinese Pharmaceutical Journal
基金
河北省医学科学研究重点课题计划资助(20170392)。